

February 25, 2021

Listing Department  
**BSE LIMITED**

**Code: 532 321**

P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

**Code: CADILAHC**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

**Re.: Press Release**

Dear Sir/Madam,

Please find enclosed a copy of press release dated February 25, 2021 titled “Zydus Cadila receives final approval from USFDA for Nortriptyline Hydrochloride Capsules.”

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**



**DHAVAL N. SONI**  
**COMPANY SECRETARY**



**Encl.: As above**

## **Zydus Cadila receives final approval from USFDA for Nortriptyline Hydrochloride Capsules**

*Ahmedabad, 25 February, 2021*

Zydus Cadila has received final approval from the USFDA to market Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg (US RLD: Pamelor Capsules).

This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, and increase one's energy level. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

\*\*\*